Sugi Predict

Sugi Predict / Compounds / SCHEMBL16035768

SCHEMBL16035768

SCHEMBL16035768

CC(=O)NC[C@@H]1CN(C(=O)OC(C)(C)C)CCO1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ RECQL P46063 1/20 0.42
▸ PDK1 Q15118 1/20 0.40
▸ EPHA2 P29317 4/20 0.40
▸ NR1H2 P55055 1/20 0.39
▸ NAMPT P43490 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ PKM P14618 1/20 0.39
▸ ERBB2 P04626 1/20 0.39
▸ EPHB4 P54760 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ GPR119 Q8TDV5 1/20 0.37
▸ EPHX1 P07099 1/20 0.36
▸ THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16035767 1.00 USP2 (0.47) USP2SMN1; SMN2RECQLPDK1EPHA2
SCHEMBL12759030 0.92 MEN1 (0.44) USP2SMN1; SMN2RECQLPDK1NR1H2
SCHEMBL16036171 0.88 USP2 (0.46) USP2SMN1; SMN2RECQLPDK1EPHA2
SCHEMBL16036173 0.88 USP2 (0.46) USP2SMN1; SMN2RECQLPDK1EPHA2
SCHEMBL16034971 0.87 USP2 (0.44) USP2SMN1; SMN2RECQLPDK1EPHA2
SCHEMBL31200524 0.87 USP2 (0.44) USP2SMN1; SMN2RECQLPDK1EPHA2
SCHEMBL19658762 0.87 USP2 (0.44) USP2SMN1; SMN2RECQLPDK1EPHA2
SCHEMBL16034970 0.87 USP2 (0.44) USP2SMN1; SMN2RECQLPDK1EPHA2
SCHEMBL22593025 0.86 USP2 (0.49) USP2SMN1; SMN2RECQLPDK1EPHA2
SCHEMBL1806955 0.86 USP2 (0.43) USP2SMN1; SMN2RECQLPDK1EPHA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108467369-B Biaryl amide compounds as kinase inhibitors 诺华股份有限公司 2021-08-20 — — CN disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 — — US disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 — — US disclosed
US-10245267-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2019-04-02 — — US disclosed
US-10245267-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2019-04-02 — — US disclosed
EP-3299367-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2018-03-28 — — EP disclosed
US-20170260207-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2017-09-14 — — US disclosed
US-20170260207-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2017-09-14 — — US disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 — — US disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 — — US disclosed
US-9242969-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2016-01-26 — — US disclosed
US-9242969-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2016-01-26 — — US disclosed
EP-2970216-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2016-01-20 — — EP disclosed
CN-105143209-A Biaryl amide compounds as kinase inhibitors NOVARTIS AG 2015-12-09 — — CN disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
WO-2014151616-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-25 — — WO disclosed
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-18 — — US disclosed
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275003-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS USP2 2371/4885SMN1; SMN2 3547/4885RECQL 1482/4885
US-10709712-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS USP2 2371/4885SMN1; SMN2 3547/4885RECQL 1482/4885
US-20170260207-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS USP2 2371/4885SMN1; SMN2 3547/4885RECQL 1482/4885
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS USP2 2371/4885SMN1; SMN2 3547/4885RECQL 1482/4885
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS USP2 2371/4885SMN1; SMN2 3547/4885RECQL 1482/4885
US-10245267-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS USP2 2371/4885SMN1; SMN2 3547/4885RECQL 1482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback